Non-invasive Urine metabolomics of Prostate Cancer and its Therapeutic Approaches: A Current Scenario and Future perspective

This article was originally published here

Expert Rev Proteomics. 2021 Nov 25. doi: 10.1080/14789450.2021.2011225. Online ahead of print.


INTRODUCTION: The sensitive, specific, fast, robust and non-invasive biomarkers for the evaluation of prostate cancer (PC) remain elusive in medical research. However, efforts are in full sway to investigate and resolve these puzzles for clinical practice. Advances in modern analytical techniques, sample processing, and the emergence of multiple omics approaches have created a great hope for the development of better detection modalities for PC. The objective of the present review is to provide a concise overview of the PC metabolomics-based potential discriminating molecules in urine samples using nuclear magnetic resonance spectroscopy and mass spectrometry.

AREA COVERED: : A literature search was executed to find the studies reporting the non-invasive urine-based biomarkers for the diagnosis and prognosis of underlying disease. Most studies have extensively reported PC discriminating molecules with their respective controls. Additionally, pathophysiology and the treatment paradigm of PC are summarised and related to the insights underpinning the therapeutic intervention of PC.

EXPERT OPINION: With multi-centric, global, comprehensive omics approaches via either a non- or least-invasive bio-matrix may open new avenues of research for PC biomarker discovery, backed by a molecular mechanistic outline.

PMID:34821179 | DOI:10.1080/14789450.2021.2011225